The former president has worked out a deal to lower the cost of top-of-the-line AIDS treatment to less than $1 a day in developing nations. That's 50 to 70 percent less, but some say it's still too much. Helen Palmer reports.
Brazil's President Lula da Silva today authorized breaking the patent on Merck's AIDS drug Efavirenz, citing the drug's price. The country will import a generic version from India instead. Helen Palmer reports.
Today's annual report on the fiscal health of the Medicare system is expected to put forth a prognosis so bleak it will trigger the program's first-ever funding warning. And even that probably won't make a difference.
The vaccine is less than 50 percent effective and only has a shelf life of 18 months, but the FDA says it's still worth approving and stockpiling — because in the event of a pandemic, saving some lives will be better than none.
An FDA panel votes today on a new Merck arthritis drug called Arcoxia. It's a super-aspirin like Vioxx, which was pulled off shelves after studies linked use to increased risks of heart attack and stroke. But does this new drug belong on the market?